| 51 |
29251327 | Survival pathway of cholangiocarcinoma via AKT/mTOR signaling to escape RAF/MEK/ERK pathway inhibition by sorafenib. | 2018 Feb |
5 |
| 52 |
29360358 | Design, Synthesis, and Preclinical Evaluation of Fused Pyrimidine-Based Hydroxamates for the Treatment of Hepatocellular Carcinoma. | 2018 Feb 22 |
2 |
| 53 |
29538717 | Sorafenib inhibits proliferation and invasion in desmoid-derived cells by targeting Ras/MEK/ERK and PI3K/Akt/mTOR pathways. | 2018 May 3 |
6 |
| 54 |
29782854 | Combined treatment with sorafenib and silibinin synergistically targets both HCC cells and cancer stem cells by enhanced inhibition of the phosphorylation of STAT3/ERK/AKT. | 2018 Aug 5 |
1 |
| 55 |
29881824 | Inhibition of insulin-like growth factor 1 receptor enhances the efficacy of sorafenib in inhibiting hepatocellular carcinoma cell growth and survival. | 2018 Jun |
1 |
| 56 |
29928334 | Inhibition of the PI3K/Akt signaling pathway reverses sorafenib-derived chemo-resistance in hepatocellular carcinoma. | 2018 Jun |
1 |
| 57 |
30021351 | microRNA-19a-3p promotes tumor metastasis and chemoresistance through the PTEN/Akt pathway in hepatocellular carcinoma. | 2018 Sep |
1 |
| 58 |
30043734 | [Sestrin 2(SESN2) promotes primary resistance to sorafenib by activating AKT in hepatocellular carcinoma cells]. | 2018 May |
2 |
| 59 |
30048489 | Autophagic cell death associated to Sorafenib in renal cell carcinoma is mediated through Akt inhibition in an ERK1/2 independent fashion. | 2018 |
3 |
| 60 |
30112114 | Applied diagnostics in liver cancer. Efficient combinations of sorafenib with targeted inhibitors blocking AKT/mTOR. | 2018 Jul 20 |
2 |
| 61 |
30154433 | ID1-induced p16/IL6 axis activation contributes to the resistant of hepatocellular carcinoma cells to sorafenib. | 2018 Aug 28 |
3 |
| 62 |
30272354 | Capsaicin and sorafenib combination treatment exerts synergistic anti‑hepatocellular carcinoma activity by suppressing EGFR and PI3K/Akt/mTOR signaling. | 2018 Dec |
1 |
| 63 |
30292139 | A Novel Aurora-A Inhibitor (MLN8237) Synergistically Enhances the Antitumor Activity of Sorafenib in Hepatocellular Carcinoma. | 2018 Dec 7 |
3 |
| 64 |
30311444 | Sestrin 2 confers primary resistance to sorafenib by simultaneously activating AKT and AMPK in hepatocellular carcinoma. | 2018 Nov |
1 |
| 65 |
30369518 | Interleukin-6 induces drug resistance in renal cell carcinoma. | 2018 Dec 8 |
1 |
| 66 |
30443188 | The HDAC Inhibitor Quisinostat (JNJ-26481585) Supresses Hepatocellular Carcinoma alone and Synergistically in Combination with Sorafenib by G0/G1 phase arrest and Apoptosis induction. | 2018 |
1 |
| 67 |
27807662 | C2-ceramide enhances sorafenib-induced caspase-dependent apoptosis via PI3K/AKT/mTOR and Erk signaling pathways in HCC cells. | 2017 Feb |
2 |
| 68 |
27873490 | EGF Induced RET Inhibitor Resistance in CCDC6-RET Lung Cancer Cells. | 2017 Jan |
1 |
| 69 |
28164434 | Dual inhibition of Akt and c-Met as a second-line therapy following acquired resistance to sorafenib in hepatocellular carcinoma cells. | 2017 Mar |
6 |
| 70 |
28276313 | Inhibition of MMP-2 Expression Enhances the Antitumor Effect of Sorafenib in Hepatocellular Carcinoma by Suppressing the PI3K/AKT/mTOR Pathway. | 2017 Nov 2 |
1 |
| 71 |
28344323 | New knowledge of the mechanisms of sorafenib resistance in liver cancer. | 2017 May |
1 |
| 72 |
28536078 | AKT is critically involved in the antagonism of BRAF inhibitor sorafenib against dabrafenib in colorectal cancer cells harboring both wild-type and mutant (V600E) BRAF genes. | 2017 Jul 15 |
3 |
| 73 |
28622037 | Inhibition of the AKT/mTOR Pathway Augments the Anticancer Effects of Sorafenib in Thyroid Cancer. | 2017 Jun |
4 |
| 74 |
28687354 | Aspirin disrupts the mTOR-Raptor complex and potentiates the anti-cancer activities of sorafenib via mTORC1 inhibition. | 2017 Oct 10 |
1 |
| 75 |
28746469 | Interleukin-27 augments the inhibitory effects of sorafenib on bladder cancer cells. | 2017 Jul 20 |
1 |
| 76 |
28903416 | Overriding TKI resistance of renal cell carcinoma by combination therapy with IL-6 receptor blockade. | 2017 Aug 15 |
1 |
| 77 |
28934275 | Activation of phosphatidylinositol 3-kinase/AKT/snail signaling pathway contributes to epithelial-mesenchymal transition-induced multi-drug resistance to sorafenib in hepatocellular carcinoma cells. | 2017 |
5 |
| 78 |
29021381 | Activation of Focal Adhesion Kinase and Src Mediates Acquired Sorafenib Resistance in A549 Human Lung Adenocarcinoma Xenografts. | 2017 Dec |
2 |
| 79 |
29152112 | Capsaicin exerts synergistic antitumor effect with sorafenib in hepatocellular carcinoma cells through AMPK activation. | 2017 Oct 20 |
1 |
| 80 |
26179270 | Potential Molecular Targeted Therapeutics: Role of PI3-K/Akt/mTOR Inhibition in Cancer. | 2016 |
2 |
| 81 |
26299635 | Combinatorial anticancer effects of curcumin and sorafenib towards thyroid cancer cells via PI3K/Akt and ERK pathways. | 2016 Aug |
1 |
| 82 |
26629768 | Sorafenib induces autophagic cell death and apoptosis in hepatic stellate cell through the JNK and Akt signaling pathways. | 2016 Mar |
2 |
| 83 |
26711788 | MK2206 overcomes the resistance of human liver cancer stem cells to sorafenib by inhibition of pAkt and upregulation of pERK. | 2016 Jun |
1 |
| 84 |
26782953 | Bufalin enhances anti-angiogenic effect of sorafenib via AKT/VEGF signaling. | 2016 Mar |
2 |
| 85 |
27095937 | Synergistic effects of sorafenib in combination with gemcitabine or pemetrexed in lung cancer cell lines with K-ras mutations. | 2016 |
1 |
| 86 |
27152946 | Inhibition of Cell Proliferation in an NRAS Mutant Melanoma Cell Line by Combining Sorafenib and α-Mangostin. | 2016 |
1 |
| 87 |
27167344 | Des-gamma-carboxy prothrombin antagonizes the effects of Sorafenib on human hepatocellular carcinoma through activation of the Raf/MEK/ERK and PI3K/Akt/mTOR signaling pathways. | 2016 Jun 14 |
2 |
| 88 |
27248172 | Integrin alphavbeta3 enhances β-catenin signaling in acute myeloid leukemia harboring Fms-like tyrosine kinase-3 internal tandem duplication mutations: implications for microenvironment influence on sorafenib sensitivity. | 2016 Jun 28 |
1 |
| 89 |
27496136 | Single Agent and Synergistic Activity of the "First-in-Class" Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma. | 2016 Nov |
1 |
| 90 |
27689326 | An artificial lncRNA targeting multiple miRNAs overcomes sorafenib resistance in hepatocellular carcinoma cells. | 2016 Nov 8 |
1 |
| 91 |
27816967 | Ubenimex attenuates acquired sorafenib resistance in renal cell carcinoma by inhibiting Akt signaling in a lipophagy associated mechanism. | 2016 Nov 29 |
2 |
| 92 |
27877053 | Synergistic activity of vorinostat combined with gefitinib but not with sorafenib in mutant KRAS human non-small cell lung cancers and hepatocarcinoma. | 2016 |
1 |
| 93 |
25416439 | Arsenic trioxide potentiates the anti-cancer activities of sorafenib against hepatocellular carcinoma by inhibiting Akt activation. | 2015 Apr |
6 |
| 94 |
25768669 | Iodide- and glucose-handling gene expression regulated by sorafenib or cabozantinib in papillary thyroid cancer. | 2015 May |
1 |
| 95 |
25778319 | Sorafenib inhibits liver cancer growth by decreasing mTOR, AKT, and PI3K expression. | 2015 Jan-Feb |
4 |
| 96 |
25862630 | Enhanced sensitivity to sorafenib by inhibition of Akt1 expression in human renal cell carcinoma ACHN cells both in vitro and in vivo. | 2015 Jul |
5 |
| 97 |
25879531 | Sorafenib inhibits intracellular signaling pathways and induces cell cycle arrest and cell death in thyroid carcinoma cells irrespective of histological origin or BRAF mutational status. | 2015 Mar 26 |
1 |
| 98 |
26097873 | Sorafenib induces cathepsin B-mediated apoptosis of bladder cancer cells by regulating the Akt/PTEN pathway. The Akt inhibitor, perifosine, enhances the sorafenib-induced cytotoxicity against bladder cancer cells. | 2015 |
6 |
| 99 |
26206949 | Sorafenib Action in Hepatitis B Virus X-Activated Oncogenic Androgen Pathway in Liver through SHP-1. | 2015 Oct |
1 |
| 100 |
26257239 | Sorafenib enriches epithelial cell adhesion molecule-positive tumor initiating cells and exacerbates a subtype of hepatocellular carcinoma through TSC2-AKT cascade. | 2015 Dec |
3 |